American Society of Hirudotherapy

Novel heparin mimetics reveal cooperativity between exosite 2 and sodium-binding site of thrombin.

Research article published in Thrombosis research (2018)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportDrug DevelopmentSalivary PharmacologyAbdel Aziz et al. · Thrombosis research, 2018

Abstract

INTRODUCTION: Thrombin is a primary target of most anticoagulants. Yet, thrombin's dual and opposing role in pro- as well as anti- coagulant processes imposes considerable challenges in discovering finely tuned regulators that maintain homeostasis, rather than disproportionately changing the equilibrium to one side. In this connection, we have been studying exosite 2-mediated allosteric modulation of thrombin activity using synthetic agents called low molecular weight lignins (LMWLs). Although the aromatic scaffold of LMWLs is completely different from the polysaccharidic scaffold of heparin, the presence of multiple negatively charged groups on both ligands induces binding to exosite 2 of thrombin. This work characterizes the nature of interactions between LMWLs and thrombin to understand the energetic cooperativity between exosite 2 and active site of thrombin. MATERIALS AND METHODS: The thermodynamics of thrombin-LMWL complexes was studied using spectrofluorimetric titrations as a function of ionic strength and temperature of the buffer. The contributions of enthalpy and entropy to binding were evaluated using classic thermodynamic equations. Label-free surface plasmon resonance was used to assess the role of sodium ion in LMWL binding to thrombin at a fixed ionic strength. RESULTS AND CONCLUSIONS: Exosite 2-induced conformational change in thrombin's active site is strongly dependent on the structure of the ligand, which has consequences with respect to regulation of thrombin. The ionic and non-ionic contributions to binding affinity and the thermodynamic signature were highly ligand specific. Interestingly, LMWLs display preference for the sodium-bound form of thrombin, which supports the existence of an energetic coupling between exosite 2 and sodium-binding site of thrombin.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAllosteric RegulationBinding SitesHeparinHumansProtein BindingThrombin

Summary

Thrombin is a primary target of most anticoagulants. Yet, thrombin's dual and opposing role in pro- as well as anti- coagulant processes imposes considerable challenges in discovering finely tuned regulators that maintain homeostasis, rather than disproportionately changing the equilibrium to one side.

Why This Matters for Hirudotherapy

This study used spectrofluorimetric titrations and surface plasmon resonance to characterize thermodynamic interactions between synthetic low molecular weight lignins (LMWLs) and thrombin's exosite 2, revealing energetic cooperativity between exosite 2 and the sodium-binding site. The abstract explicitly notes that LMWLs have an aromatic scaffold completely different from heparin's polysaccharidic scaffold, yet both bind exosite 2 through multiple negatively charged groups, with LMWLs displaying preference for the sodium-bound form of thrombin. The abstract makes no mention of leeches, hirudotherapy, hirudin, or any leech-derived compounds. This article has no defensible relevance to hirudotherapy or the leech secretome.

Citation

Novel heparin mimetics reveal cooperativity between exosite 2 and sodium-binding site of thrombin.

Abdel Aziz et al. · Thrombosis research, 2018

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.